137 related articles for article (PubMed ID: 21833673)
1. Treatment with Huperzine A improves cognition in vascular dementia patients.
Xu ZQ; Liang XM; Juan-Wu ; Zhang YF; Zhu CX; Jiang XJ
Cell Biochem Biophys; 2012 Jan; 62(1):55-8. PubMed ID: 21833673
[TBL] [Abstract][Full Text] [Related]
2. [Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial].
Zhang Z; Wang X; Chen Q; Shu L; Wang J; Shan G
Zhonghua Yi Xue Za Zhi; 2002 Jul; 82(14):941-4. PubMed ID: 12181083
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of huperzine A in mild to moderate Alzheimer disease.
Rafii MS; Walsh S; Little JT; Behan K; Reynolds B; Ward C; Jin S; Thomas R; Aisen PS;
Neurology; 2011 Apr; 76(16):1389-94. PubMed ID: 21502597
[TBL] [Abstract][Full Text] [Related]
4. Donepezil in vascular dementia: combined analysis of two large-scale clinical trials.
Román GC; Wilkinson DG; Doody RS; Black SE; Salloway SP; Schindler RJ
Dement Geriatr Cogn Disord; 2005; 20(6):338-44. PubMed ID: 16192723
[TBL] [Abstract][Full Text] [Related]
5. Galantamine treatment of vascular dementia: a randomized trial.
Auchus AP; Brashear HR; Salloway S; Korczyn AD; De Deyn PP; Gassmann-Mayer C;
Neurology; 2007 Jul; 69(5):448-58. PubMed ID: 17664404
[TBL] [Abstract][Full Text] [Related]
6. Huperzine a as potential treatment of Alzheimer's disease: an assessment on chemistry, pharmacology, and clinical studies.
Ha GT; Wong RK; Zhang Y
Chem Biodivers; 2011 Jul; 8(7):1189-204. PubMed ID: 21766442
[TBL] [Abstract][Full Text] [Related]
7. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
[TBL] [Abstract][Full Text] [Related]
8. [An experimental, randomized, double-blind, placebo-controlled clinical trial to infestigate the effect of nicardipine on cognitive function in patients with vascular dementia. Spanish group of nicardipine study in vascular dementia].
Rev Neurol; 1999 May 1-15; 28(9):835-45. PubMed ID: 10390744
[TBL] [Abstract][Full Text] [Related]
9. Huperzine A for vascular dementia.
Hao Z; Liu M; Liu Z; Lv D
Cochrane Database Syst Rev; 2009 Apr; (2):CD007365. PubMed ID: 19370686
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
11. Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.
Yang G; Wang Y; Tian J; Liu JP
PLoS One; 2013; 8(9):e74916. PubMed ID: 24086396
[TBL] [Abstract][Full Text] [Related]
12. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease.
Xu SS; Gao ZX; Weng Z; Du ZM; Xu WA; Yang JS; Zhang ML; Tong ZH; Fang YS; Chai XS
Zhongguo Yao Li Xue Bao; 1995 Sep; 16(5):391-5. PubMed ID: 8701750
[TBL] [Abstract][Full Text] [Related]
14. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of Fufangdanshen tablets (Radix Salviae miltiorrhizae formula tablets) for mild to moderate vascular dementia: a study protocol for a randomized controlled trial.
Tian J; Shi J; Wei M; Qin R; Ni J; Zhang X; Li T; Wang Y
Trials; 2016 Jun; 17(1):281. PubMed ID: 27266867
[TBL] [Abstract][Full Text] [Related]
16. Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study.
Weyer G; Eul A; Milde K; Wierich W; Herrmann WM
Pharmacopsychiatry; 2000 May; 33(3):89-97. PubMed ID: 10855459
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial.
Ditzler K
Arzneimittelforschung; 1991 Aug; 41(8):773-80. PubMed ID: 1781796
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled clinical trial of the Chinese herbal medicine "ba wei di huang wan" in the treatment of dementia.
Iwasaki K; Kobayashi S; Chimura Y; Taguchi M; Inoue K; Cho S; Akiba T; Arai H; Cyong JC; Sasaki H
J Am Geriatr Soc; 2004 Sep; 52(9):1518-21. PubMed ID: 15341554
[TBL] [Abstract][Full Text] [Related]
19. Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia.
Villardita C; Parini J; Grioli S; Quattropani M; Lomeo C; Scapagnini U
J Neural Transm Suppl; 1987; 24():293-8. PubMed ID: 3479527
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of Tianmabianchunzhigan in mild to moderate vascular dementia: Protocol of a randomized controlled IIa trial.
Tian J; Shi J; Wei M; Li T; Ni J; Zhang X; Zhang M; Li Y; Wang Y
Medicine (Baltimore); 2018 Dec; 97(51):e13760. PubMed ID: 30572524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
